Medincell stock breaks through its 24.66 € resistance following a Stifel upgrade
The Montpellier-based biopharmaceutical company posts the strongest gain in its index, in a well-oriented Paris market. The rebound occurs just days after a series of difficult sessions and is accompanied by a new analyst opinion.
A resistance broken through and a price now above the three moving averages
Medincell surges 14.48% to 26.40 €, compared to 23.06 € at the previous close, and ranks first in the SBF 120. The security broke through its 24.66 € resistance level during the session and is holding above it. It simultaneously rises back above its MA20 (22.59 €), MA50 (23.81 €) and MA200 (24.78 €), which changes the technical configuration observed in recent weeks.
This rebound partly erases the 10.57% decline recorded over three months, while the security is already up 10.65% for the week. The RSI, at 49, remains neutral despite the magnitude of the move. The next resistance stands at 29.56 €, while support is at 21.40 €.
Stifel raises its target to 36.50 € and initiates a potential of 38% versus the current price
Stifel raises its price target from 33.00 € to 36.50 € and maintains a buy rating on the security on October 6. This target offers a potential of approximately 38% compared to the price of 26.40 €. The consensus of reviewed analysts, summarized on the analysts' opinions and consensus page, provides an additional reference.
On valuation, according to the consensus of reviewed analysts, the security is trading at approximately 528 times the earnings of the current fiscal year and 62.9 times those of the following fiscal year. The security had already advanced 2.5% in the previous session, after a difficult quarter.
